lobbying_activities: 3488765

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3488765	401ee552-0bb5-44b4-8573-5a32ee7fc7a0	Q4	MEHLMAN CONSULTING, INC.	284950	THE CAMPAIGN FOR SUSTAINABLE RX PRICING	2025	fourth_quarter	PHA	Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 1067 - Ensuring Timely Access to Generics Act; S. 2630 - REMEDY Act; H.R.1262 - Mikaela Naylon Give Kids a Chance Act.	HOUSE OF REPRESENTATIVES,SENATE	90000		0	0	2026-01-16T12:09:15-05:00